REPLIMUNE GROUP, INC. Pre-Tax Income
REPLIMUNE GROUP, INC. (REPL) reported Pre-Tax Income of -$314.49 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-06-29
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$73.46M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$71.24M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-03-31 was -$74.24M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2024-12-31 was -$65.77M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2026 was -$314.49M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$246.83M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$215.39M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$174.00M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$73.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$144.70M derived: sum of 2 quarters · filed 2026-06-29 | -$314.49M 10-K · filed 2026-06-29 | |
| 2025-12-31 | -$71.24M 10-Q · filed 2026-02-03 | -$241.03M 10-Q · filed 2026-02-03 | ||
| 2025-03-31 | -$74.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$140.00M derived: sum of 2 quarters · filed 2026-06-29 | -$193.06M derived: sum of 3 quarters · filed 2026-06-29 | -$246.83M 10-K · filed 2026-06-29 |
| 2024-12-31 | -$65.77M 10-Q · filed 2026-02-03 | -$118.82M derived: sum of 2 quarters · filed 2026-02-03 | -$172.59M 10-Q · filed 2026-02-03 | -$227.73M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | -$53.05M 10-Q · filed 2024-11-12 | -$106.83M 10-Q · filed 2024-11-12 | -$161.97M derived: sum of 3 quarters · filed 2025-05-22 | -$212.61M derived: sum of 4 quarters · filed 2025-05-22 |
| 2024-06-30 | -$53.77M 10-Q · filed 2024-08-08 | -$108.91M derived: sum of 2 quarters · filed 2025-05-22 | -$159.56M derived: sum of 3 quarters · filed 2025-05-22 | -$219.80M derived: sum of 4 quarters · filed 2025-05-22 |
| 2024-03-31 | -$55.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | -$105.79M derived: sum of 2 quarters · filed 2025-05-22 | -$166.03M derived: sum of 3 quarters · filed 2025-05-22 | -$215.39M 10-K · filed 2025-05-22 |
| 2023-12-31 | -$50.65M 10-Q · filed 2025-02-12 | -$110.89M derived: sum of 2 quarters · filed 2025-02-12 | -$160.25M 10-Q · filed 2025-02-12 | -$209.20M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$60.24M 10-Q · filed 2024-11-12 | -$109.60M 10-Q · filed 2024-11-12 | -$158.55M derived: sum of 3 quarters · filed 2024-11-12 | -$198.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$49.35M 10-Q · filed 2024-08-08 | -$98.31M derived: sum of 2 quarters · filed 2024-08-08 | -$138.00M derived: sum of 3 quarters · filed 2024-08-08 | -$181.10M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$48.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | -$88.64M derived: sum of 2 quarters · filed 2024-05-16 | -$131.74M derived: sum of 3 quarters · filed 2024-05-16 | -$174.00M 10-K · filed 2024-05-16 |
| 2022-12-31 | -$39.69M 10-Q · filed 2024-02-08 | -$82.79M derived: sum of 2 quarters · filed 2024-02-08 | -$125.05M 10-Q · filed 2024-02-08 | |
| 2022-09-30 | -$43.10M 10-Q · filed 2023-11-07 | -$85.36M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$42.25M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$118.04M 10-K · filed 2023-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |